Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered and integrated teams. She has broad experience integrating science, business and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning in immuno-oncology, immunoscience, fibrosis and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory and drug development. An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.
Wendy Winckler, Ph.D.
Chief Scientific Officer
Wendy Winckler is an experienced scientific leader with a strong track record in oncology, genomics, bioinformatics, and translational research. Prior to joining Glympse, she was the Executive Director of Next Generation Diagnostics at the Novartis Institutes of Biomedical Research. There she built a team to develop and employ innovative genomic technologies and analytic methods to study biomarkers of response and resistance in oncology clinical trials. Previously, Wendy was the Director of the Genetic Analysis Platform at the Broad Institute of MIT and Harvard and co-principal investigator of the NIH Genotype-Tissue Expression (GTEx) program. Wendy studied genetics at UCLA and Harvard.
Eric K. Huang, Ph.D.
Chief Development Officer
Eric is a life science executive with 20 years of strategic and operational experience across both scientific and business functions within early-stage companies. He specializes in advancing innovative and cutting-edge technology platforms from concept to clinic. Eric joined Glympse Bio as its first full-time employee in 2016 and was responsible for building the R&D team and launching operations. Previously, he was a Program Executive at Epirus Biopharmaceuticals where he led multiple biosimilar programs as well as managing key international alliances. Prior to that, Eric was General Manager and Head of Operations at Acusphere, where he was responsible for R&D, regulatory affairs, manufacturing, business development, and intellectual property. Eric has a B.S. in Biomedical Engineering from Brown University, Master’s in Biomedical Engineering from Rutgers University, and Ph.D. in Medical Science from Brown University.
Roopom Banerjee, MPP
Chief Business Officer
Roopom is a life science business leader with 20 years experience covering strategy, financial advisory, operational and scientific roles. He has broad experience with startups to global Fortune 500 companies advising on corporate strategy, portfolio design, product development and commercialization, financing, partnerships and acquisitions. Most recently, he was President and CEO of RainDance Technologies (acquired by BioRad Labs) and led the company to become a pioneer in Liquid Biopsy for detecting cancer from a blood test. Previously, Roopom led teams at McKinsey, Leerink and Goldman Sachs where he completed 80+ healthcare transactions raising over $10Bn in capital financings, 30+ IPOs, and 20+ M&A transactions. His earlier career spanned scientific cancer research at the Dana Farber Cancer Institute and Human Genome Project. A biochemist and economist by training, Roopom has a graduate degree from Harvard and two undergrad degrees from MIT where he was elected a Howard Hughes Medical Institute Scholar.
Martha Denyer, MBA
Vice President, Finance
Martha is a senior financial professional with extensive experience designing and building financial planning and reporting solutions. Experience in both public and private companies in the Biotechnology, High Tech and Software industries. Proven ability to build finance teams, implement financial planning, forecasting and budgeting processes and systems, providing accurate and insightful analysis to senior level executives and investors and lead teams through M&A due diligence and post-acquisition integration. Most recently she was Vice President at Neutron Therapeutics where she established the Finance function for the company. Martha has a undergraduate and masters in Business Administration from Northeastern University.